Skip to main content
. 2022 Jun 10;7(3):100506. doi: 10.1016/j.esmoop.2022.100506

Figure 1.

Figure 1

Median progression-free survival (mPFS) for overall population, doublet, and triplet.

Bini, binimetinib; Cetux, cetuximab; CI, confidence interval; Enco, encorafenib; HR, hazard ratio; mos, months; mPFS, median progression-free survival; n, number.